IP Library Granted Patent US 7,445,628
Granted Patent B2
US 7,445,628 · App. 10/414,444 · Granted Nov 4, 2008

Method of treating a patient with a coated implantable medical device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,445,628
App. No.
10/414,444
Granted
Nov 4, 2008
Kind
B2
Abstract

Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a controlled release of the bioactive.

Claims (18)

1. A method of treating a human or veterinary patient, comprising implanting a vascular stent at a point of treatment within the vascular system of a human or veterinary patient, the vascular stent comprising a surface, a coating layer consisting of a parylene polymer posited on the surface of the vascular stent, a layer comprising an immunosuppressive agent posited on at least a portion of the coating layer, and a porous layer comprising a second polymer overlaying the layer comprising the immunosuppressive agent.

2. The method of claim 1 , wherein the surface of the vascular stent comprises stainless steel.

3. The method of claim 1 , wherein about 0.01 mg to about 10 mg of the immunosuppressive agent is present per cm 2 of the gross surface area of the vascular stent.

4. The method of claim 1 , wherein about 0.1 mg to about 4 mg of the immunosuppressive agent is present per cm 2 of the gross surface area of the vascular stent.

5. A method of inhibiting restenosis in a blood vessel, comprising deploying a vascular stent in a blood vessel, the vascular stent comprising a surface, a coating layer consisting of a parylene or a parylene derivative polymer posited on the surface of the vascular stent, a layer comprising an immunosuppressive agent posited on at least a portion of the coating layer, and a porous layer comprising a second polymer overlaying the layer comprising the immunosuppressive agent and having a thickness adequate to provide a controlled release of the immunosuppressive agent.

6. The method of claim 5 , wherein the coating layer consists of the parylene derivative polymer.

7. The method of claim 5 , wherein about 0.01 mg to about 10 mg of the immunosuppressive agent is present per cm 2 of the gross surface area of the vascular stent.

8. The method of claim 5 , wherein about 0.1 mg to about 4 mg of the immunosuppressive agent is present per cm 2 of the gross surface area of the vascular stent.

9. The method of claim 1 , wherein the thickness of the porous layer provides for a controlled release of the immunosuppressive agent through the porous layer.

10. A method of treating a human or veterinary patient, comprising implanting a vascular stent at a point of treatment within the vascular system of a human or veterinary patient, the vascular stent comprising a surface, a coating layer consisting of parylene or a parylene derivative polymer posited on the surface of the vascular stent, a layer comprising a second polymer attached to an immunosuppressive agent, and a porous layer comprising a third polymer overlaying the layer comprising the immunosuppressive agent and having a thickness adequate to provide a controlled release of the immunosuppressive agent.

11. The method of claim 10 , wherein the coating layer consists of the parylene derivative polymer.

12. The method of claim 10 , wherein the porous layer consists of the third polymer.

13. The method of claim 1 , wherein the coating layer has a thickness of about 50,000 to 500,000 Angstroms.

14. The method of claim 1 , wherein the porous layer has a thickness of about 5,000 to 250,000 Angstroms.

15. The method of claim 10 , wherein 0.1 mg to 4 mg of the immunosuppressive agent is present per cm 2 of gross surface area of the vascular stent.

16. The method of claim 1 , wherein the coating layer has a thickness of about 50,000 to 500,000 Angstroms;

the layer comprising the immunosuppressive agent contains a total of about 0.1 mg to 4 mg of immunosuppressive agent per cm 2 of the gross surface area of the vascular stent and the porous layer has a thickness of about 5,000 to 250,000 Angstroms; and

the vascular stent is about 10 mm to about 60 mm in length and is designed to expand to a diameter of about 2 mm to about 6 mm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2011
From: MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC., (D/B/A MED INSTITUTE, INC.)
To: COOK MEDICAL TECHNOLOGIES LLC
Reel/Frame 026444/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: COOK INCORPORATED; WILSON-COOK MEDICAL INCORPORATED; VANCE PRODUCTS INCORPORATED; COOK VASCULAR INCORPORATED; SABIN CORPORATION
To: COOK MEDICAL TECHNOLOGIES LLC
Reel/Frame 026287/0923 →